DARA BioSciences Inc. (NASDAQ:DARA) climbed 15.18% after the company reported that KRN5500 has won the FDA’s Orphan Drug Designation. DARA Biosciences Inc. (NASDAQ:DARA) stock opened today at $1.34 and is currently trading at $1.33. The stock showed a negative weekly performance of -1.75%.
Sequenom, Inc. (NASDAQ:SQNM) announced Monday that it has received premarket 510(k) clearance from the United States Food and Drug Administration (FDA) to market its IMPACT Dx Factor V Leiden and Factor II Genotyping Test and the IMPACT Dx System. Sequenom, Inc. (NASDAQ:SQNM) stock opened at $3.20, in current trading session and currently is at $3.34, by gaining 8.99%. The 52 week range of $1.65 – $4.90. Company’s market capitalization is 388.19 million.
Maxim said its recent meeting with Achillion Pharmaceuticals, Inc.(NASDAQ:ACHN) management made it believe that fundamental progress will be made by the company and that IP for its HCV nucleotide could be a catalyst. The firm raised its price target on the stock to $22 from $6 and maintains its Buy rating on the shares. Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) stock is currently trading at $7.39. The EPS of the stock is -0.65. Company’s market capitalization is 715.32 million.
Covidien Plc (NYSE:COV) surged 28 percent after Medtronic Inc. agreed to buy the Irish company for $42.9 billion. Covidien plc (NYSE:COV) stock opened the session at $92.35, and now is at $91.18. The 52 week range of the Covidien plc (NYSE:COV) stock remained $56.79 – $92.68 and the day range was $90.89 – $92.68.
Arrowhead Research Corporation (NASDAQ:ARWR), a biopharmaceutical company developing targeted RNAi therapeutics, today reaffirmed its belief that it has broad access to intellectual property required to develop ARC-520, its clinical candidate against chronic hepatitis B infection. The Company has licenses to relevant patents and patent applications enabling the development and commercialization of ARC-520 in key pharmaceutical markets globally. Arrowhead does not believe there are additional unlicensed patents directed to RNAi therapeutics targeting the hepatitis B virus that affect its freedom to operate. Arrowhead Research Corp (NASDAQ:ARWR) stock opened today at $13.14 and is currently trading at $13.29. The stock showed a negative weekly performance of -13.23%.
Leave a Reply